Literature DB >> 4015727

Influence of the severity and duration of murine antigen-induced arthritis on cartilage proteoglycan synthesis and chondrocyte death.

M W Kruijsen, W B van den Berg, L B van de Putte.   

Abstract

Recent studies have shown that joint inflammation can suppress chondrocyte proteoglycan synthesis and can even kill chondrocytes. In the present study, we investigated the influence of the severity and chronicity of murine antigen-induced arthritis on the degree of these toxic effects on chondrocytes. Joint inflammation, quantitated by measurements of 99m technetium pertechnetate uptake, was significantly correlated with the inhibition of proteoglycan synthesis, measured by 35S-sulfate incorporation. Histologic grading of the extent of chondrocyte death on day 28 after arthritis induction correlated best with the degree of inflammation present on day 14. High scores for chondrocyte death were found only in mice with persistent, severe arthritis. Our data indicate that the severity of joint inflammation is a major determinant of the degree of chondrocyte proteoglycan synthesis inhibition, whereas both the severity and chronicity of the inflammation determine chondrocyte killing and, therefore, irreversible joint destruction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015727     DOI: 10.1002/art.1780280713

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Short-term immobilization restores and prevents inhibition of chondrocyte synthesis caused by IL-1.

Authors:  P L van Lent; A A van de Loo; L van den Bersselaar; W B van den Berg
Journal:  Agents Actions       Date:  1989-01

2.  Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis.

Authors:  J B van Meurs; P L van Lent; A A van de Loo; A E Holthuysen; E K Bayne; I I Singer; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1999-06       Impact factor: 19.103

3.  Degenerative knee joint lesions in mice after a single intra-articular collagenase injection. A new model of osteoarthritis.

Authors:  P M van der Kraan; E L Vitters; H M van Beuningen; L B van de Putte; W B van den Berg
Journal:  J Exp Pathol (Oxford)       Date:  1990-02

4.  Effects of murine recombinant interleukin 1 on intact homologous articular cartilage: a quantitative and autoradiographic study.

Authors:  W B van den Berg; F A van de Loo; W A Zwarts; I G Otterness
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

5.  Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints.

Authors:  P M van der Kraan; E L Vitters; L B van de Putte; W B van den Berg
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

6.  Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment.

Authors:  W B van den Berg; L A Joosten; M Helsen; F A van de Loo
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Protective effect of rimexolone on cartilage damage in arthritic mice: a comparative study with triamcinolone hexacetonide.

Authors:  L A Joosten; M M Helsen; W B van den Berg
Journal:  Agents Actions       Date:  1990-08

8.  Electrical charge and joint inflammation. Suppression of cationic aBSA-induced arthritis with a competitive polycation.

Authors:  W B van den Berg; L A Joosten; L B van de Putte; W A Zwarts
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

9.  Quantitation of glycosaminoglycan metabolism in anatomically intact articular cartilage of the mouse patella: in vitro and in vivo studies with 35S-sulfate, 3H-glucosamine, and 3H-acetate.

Authors:  B J de Vries; W B van den Berg; E Vitters; L B van de Putte
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

10.  Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac.

Authors:  M A Hayward; G A Howard; R G Neuman; D D Wood; B M Weichman; D C Van Sickle
Journal:  Agents Actions       Date:  1989-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.